Sandra Peiró

Medicine · Health Sciences

30h-index3.7kcitations102works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(31), Peptidase Inhibition and Analysis(26), RNA modifications and cancer(19), Epigenetics and DNA Methylation(12), Cancer-related gene regulation(12)

Publications102 total

Supplementary Figure S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Figure S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Figure S6 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Figure S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Figure S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Figure S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
Supplementary Table S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025Open Access
<scp>LOXL</scp> 2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells
FEBS Journal·2024· 2 citedOpen Access
Author response for "&lt;scp&gt;LOXL&lt;/scp&gt;2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells"
2024
Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models
Methods in molecular biology·2024· 2 cited
Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer
EMBO Molecular Medicine·2023· 11 citedOpen Access
Author response for "&lt;scp&gt;LOXL&lt;/scp&gt;2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells"
2023
Author Reply to Peer Reviews of Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer
2023
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Frontiers in Oncology·2023· 51 citedOpen Access
Carm1-arginine methylation of the transcription factor C/EBPα regulates transdifferentiation velocity
eLife·2023· 6 citedOpen Access
Author response: Carm1-arginine methylation of the transcription factor C/EBPα regulates transdifferentiation velocity
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Antonio Garcı́a de Herreros(20), Laura Pascual‐Reguant(9), Alba Millanes‐Romero(9), Luciano Di Croce(8), Ane Iturbide(8), Natàlia Dave(7), Nicolás Herranz(6), Víctor M. Diaz(6), Gemma Serra‐Bardenys(6), Joan Pau Cebrià‐Costa(6), Joaquı́n Arribas(6), Tian V. Tian(6), Celia Jerónimo(5), Gaetano Verde(5), Travis H. Stracker(5), Enrique Blanco(4), Carlos Enrich(4), Jessica Querol(4), Paolo Nucíforo(4), Marta Escorihuela(4)